Gena Coelho, APRN
Adult Health · New Haven, CTNPI 1467882787
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 371 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AbbVie at 43.0% of the total. Among adult health clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 371 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- SK Life Science, Inc.$507
- Argenx US, Inc.$387
- AstraZeneca$337
- Lilly USA, LLC$331
- UCB, Inc.$326
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,899100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 206 | $2,964 |
| SK Life Science, Inc. | 20 | $507 |
| Argenx US, Inc. | 12 | $387 |
| AstraZeneca | 17 | $337 |
| Lilly USA, LLC | 17 | $331 |
| UCB, Inc. | 9 | $326 |
| Neurocrine Biosciences, Inc. | 10 | $309 |
| EMD Serono, Inc. | 10 | $199 |
| Bristol Myers Squibb | 7 | $148 |
| Biogen | 6 | $139 |
| Lundbeck LLC | 5 | $108 |
| Eisai Inc. | 5 | $105 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $102 |
| Pfizer | 5 | $99 |
| Axsome Therapeutics, Inc. | 3 | $93 |
| Otsuka America Pharmaceutical, Inc. | 4 | $90 |
| Biohaven Pharmaceuticals, Inc. | 2 | $86 |
| Scilex Pharmaceuticals Inc. | 4 | $79 |
| Amgen | 3 | $69 |
| Amneal Pharmaceuticals LLC | 3 | $49 |
| Tanabe Pharma America, Inc. | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Merz Pharmaceuticals, LLC | 1 | $33 |
| Upsher-smith Laboratories LLC | 2 | $31 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Globus Medical | 1 | $26 |
| Life Molecular Imaging Ltd | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Grifols USA, LLC | 1 | $20 |
| Nevro Corp. | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Avion Pharmaceuticals | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $17 |
How this compares
$6,899 in reported general payments places this provider in the 90th percentile of 418 adult health providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 101 | $175,258 |
| Avonex (4 Pack)Interferon Beta-1a | 15 | $122,301 |
| UbrelvyUbrogepant | 47 | $63,962 |
| QuliptaAtogepant | 29 | $41,561 |
| VimpatLacosamide | 15 | $40,068 |
| Emgality PenGalcanezumab-Gnlm | 12 | $14,091 |
| NamzaricMemantine Hcl/Donepezil Hcl | 15 | $11,989 |
| Lacosamide | 76 | $10,071 |
| Emgality SyringeGalcanezumab-Gnlm | 13 | $9,755 |
| Memantine Hcl ErMemantine Hcl | 111 | $9,610 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $9,305 |
| Carbamazepine ErCarbamazepine | 41 | $5,690 |
| Levetiracetam | 176 | $4,550 |
| Gabapentin | 139 | $2,820 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 117 | $2,800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $99 | $175,258101 claims |
| BiogenAvonex (4 Pack) | $139 | $122,30115 claims |
| AbbVieUbrelvy, Qulipta, Namzaric | $2,964 | $117,51291 claims |
| UCB, Inc.Vimpat | $326 | $40,06815 claims |
| Upsher-smith Laboratories LLCTopiramate | $31 | $1,829102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 418 adult health providers in Connecticut.
Other adult health in New Haven
- Kellie HaleNew Haven$27K
- Amy DavisNew Haven$6K
- Elyssa NoceNew Haven$5K
- Emily DuffieldNew Haven$4K
- Kathleen CrawfordNew Haven$4K
- Leah EhleManchester$418K
- Laura MulkaWethersfield$306K
- Gretchen MichaelsonSouth Windsor$169K
- Kimberly RyanWethersfield$74K
- Kathryn JackMeriden$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.